Innovent Biologics, Inc. develops, manufactures and commercializes biopharmaceutical medicines for oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas. News from Innovent centers on product approvals and commercial updates in China, clinical and preclinical data for pipeline assets, medical-congress presentations, and partner-reported development updates. Recurring drug and program references include mazdutide for type 2 diabetes, IBI363 in cancer immunotherapy, IBI324/OLN324 for retinal disease, tigulixostat/IBI128 for gout, and immunology assets such as picankibart/IBI112, IBI3013 and IAR129.
Innovent Biologics, Inc. receives NMPA Breakthrough Therapy Designation for IBI343 as monotherapy for advanced gastric cancer. The designation is based on promising Phase 1 study results showing safety, tolerability, and antitumor activity in advanced GC patients. Innovent plans to conduct a Phase 3 clinical trial soon. The company aims to provide effective third-line treatment options for GC patients in need.
Innovent Biologics, Inc. appoints Dr. Samuel Zhang as Global Chief Business Officer, bringing over 20 years of industry experience. Dr. Zhang will lead global strategy and business development, reporting to Dr. Michael Yu. His expertise includes identifying industry trends, R&D decision-making, and strategic transactions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.